Abstract
Problem definition This paper considers how to allocate COVID-19 vaccines to different age groups when limited vaccines are available over time.
Academic/practical relevance Vaccine is one of the most effective interventions to contain the ongoing COVID-19 pandemic. However, the initial supply of the COVID-19 vaccine will be limited. An urgent problem for the government is to determine who to get the first dose of the future COVID-19 vaccine.
Methodology We use epidemic data from New York City to calibrate an age-structured SAPHIRE model that captures the disease dynamics within and across various age groups. The model and data allow us to derive effective static and dynamic vaccine allocation policies minimizing the number of confirmed cases or the numbers of deaths.
Results The optimal static policies achieve a much smaller number of confirmed cases and deaths compared to other static benchmark policies including the pro rata policy. Dynamic allocation policies, including various versions of the myopic policy, significantly improve on static policies.
Managerial implications For static policies, our numerical study shows that prioritizing the older groups is beneficial to reduce deaths while prioritizing younger groups is beneficial to avert infections. For dynamic policies, the older groups should be vaccinated at early days and then switch to younger groups. Our analysis provides insights on how to allocate vaccines to the various age groups, which is tightly connected to the decision-maker’s objective.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We add a literature review section and discussion on the trade-off between efficiency and equity.
Data Availability
The datasets used in this paper are available in the NYC Department of Health and Mental Hygiene and Baruch College.
https://www1.nyc.gov/site/doh/covid/covid-19-data.page
https://www.baruch.cuny.edu/nycdata/population-geography/age_distribution.htm
